(0) Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the issuance of a second tranche of 650,000 equity warrants within the framework of the contingent equity line with Kepler Cheuvreux. On September 27, 2018, CARMAT put in place a contingent equity line contract with Kepler Cheuvreux for a maximum amount of €25 million for a duration of 3 years. The first tranche of 400,000 equity warrants, issued in September 2018, has, to date, enabled the Company to benefit from €9.1 million in financing within the framework of this contract.